Please Wait.....
Report
Artificial Blood: Global Markets to 2028
Market Research Report I 2023-08-29 I 120 Pages I BCC Research
Description
Report Scope:
The scope of this study encompasses an investigation of the global market for artificial blood, focusing on various important aspects of the market, such as research and development, clinical trial outcomes, approval status, and the potential commercial demand for artificial blood products. The report includes a discussion of artificial oxygen carrier products. BCC Research analyzes each market segment and provides a forecast for six years. The current report analyzes the market's drivers, challenges, and opportunities. The report also covers market projections for 2028 and the market analysis for key market players. The report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides information on emerging technologies, the impact of COVID-19, product analysis, deals, and investment outlook.
Report Includes:
- 41 tables
- An overview of the global markets for artificial blood
- Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Highlights of the market potential and characterization of artificial blood market by product, application, and region
- Examination of the key drivers and constraints that will shape the market and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and sub-segments
- Coverage of recent advances, emerging technologies, and developments of the industry
- Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry
- Company profiles of major players within the industry, including Hemarina, VirTechBio, and NuvOx Pharma
Executive Summary
Summary:
The human body contains a vital fluid called blood, which delivers oxygen and nutrients to the body's cells and carries waste products away from the cells in a gas exchange process. The artificial blood being developed is intended to satisfy some of the functions of biological blood, particularly in humans.
Currently, two fundamental approaches to artificial blood are being taken: perfluorocarbons and hemoglobin-based oxygen carriers.
Safe and timely access to blood transfusion is crucial for saving lives and enhancing health. Unfortunately, numerous patients needing transfusions face difficulty obtaining secure blood supplies promptly. Blood transfusions are done for several conditions, such as severe injury or trauma with significant blood loss, surgery, childbirth, anemia, cancer, kidney failures and others. The blood shortage and the risks and challenges associated with donor blood have led to the development of artificial blood. Notably, the potential market for artificial blood is very high, and estimated to be around $REDACTED billion in 2028 and hence the market needs products which would cater to such high unmet need.
The research for finding a potential alternative for blood, has been ongoing for centuries, but the results have been disappointing. This is mainly because of the adverse reactions associated with the developed products. Because of this, these products have been terminated or discontinued during clinical development. The poor success rate of the products led to losses for the companies, because of which they have filed for bankruptcy or are out of business.
Recently, it has been observed that companies are focusing on developing products that would address the shortcomings of the failed or existing products in the pipeline. Some of these include the development of freeze-dried HBOCs, Erythromer (from Kalocyte) (which is based on nanocapsule technology), and biosynthetic red blood cells (producing red blood cells from stem cells), being developed by companies such as Erypharma and Red C Biotech. Researchers are also focusing on the development of artificial whole blood by combining three synthetic components: freeze-dried platelet surrogates, freeze-dried red blood cell surrogates, and freeze-dried plasma.
The artificial blood market was estimated to be $REDACTED million in 2022 and is forecasted to grow at a compound annual growth rate (CAGR) of REDACTED% to reach a value of $REDACTED million through 2028. The market value is low because there are no approved products for artificial blood. Hemopure is the only marketed product for anemia and is approved in South Africa and Russia and used under an expanded access program in the U.S. Currently, the company doesn't have the infrastructure and funds to produce the product and the company reported no revenue in 2021. In 2022, HemO2life from Hemarina was approved for use as an additive for kidney grafts in the European Union. There are no approved
products for routine clinical use in the U.S., which is the primary market. A similar product for graft preservation is being developed by VirTechBio-OxyBridge-which is in development and anticipated to enter the U.S. market by 2026. There are companies with products in Phase II and Phase II/III development, but the products might not be approved in the forecast period or enter the market by 2028. However, future approvals will help cater to the high unmet need in the market.
Factors leading to the growth of the market are increasing demand for blood transfusions and risks and challenges associated with blood transfusions and shortage of blood supply. Factors such as low rate of approvals, product acceptance, and higher pricing act as barriers to the market. The market is dominated by startup and private biotech companies. Key players in the market include Hemarina, NuvOx Pharmaceuticals, VirTech Bio, and Prolong Pharmaceuticals.
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What's New in This Update?
Methodology
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Overview
Chapter 3 Market Overview
Introduction
Is There a Problem with Human Blood?
Emerging Needs for Artificial Blood
Artificial Blood Will Be Useful in Dealing with the Risks of Infection
Artificial Blood Will Help to Decrease the Load on the Donor Blood Supply
Artificial Blood Is Needed to Deal with Unexpected Demands on the Blood System
Hurdles in the Development of Artificial Blood Products
Ideal Characteristics of Artificial Blood
Artificial Blood Over Human Blood
Applications
Surgeries
Emergency Resuscitation
For Short-term Use
Where More Effective Than Human Blood
Rejections Due to Religious Beliefs
Challenges in Artificial Blood Development
Chapter 4 Market Dynamics
Drivers
Increasing Demand for Blood Transfusions
Risks and Challenges Associated with Blood Transfusions
Shortage of Blood Supply
Barriers
Low Rate of Product Approvals
Product Acceptance
Product Pricing
Opportunities
Impact of COVID-19
Chapter 5 Artificial Blood by Source
Introduction
Artificial Blood Developed from Human Blood
Artificial Blood Developed from Animal Blood
Artificial Blood Developed Using Recombinant Technology
Surface Modified Hemoglobin
Cross-Linked Hemoglobin
Polymerized Hemoglobin
Encapsulation
Genetically Engineered Recombinant Hemoglobin
Natural Hemoglobin
Chapter 6 Artificial Blood by Type
Introduction
Perfluorocarbon Emulsions
General Characteristics of Perfluorocarbons
Emulsion Selection
Historical Developments of Perfluorocarbon Emulsions
First Generation of PFCs
Second Generation of PFCs
Third Generation of PFCs
Hemoglobin-based Oxygen Carriers
General Characteristics of HBOCs
Historical Events: Hemoglobin Solutions
Chapter 7 Market Estimation
Introduction
Potential Market for Artificial Blood
Artificial Blood Market, by Source
Blood (Animal/Human)
Synthetic Polymers
Artificial Blood Market, by Type
Hemoglobin-based Oxygen Carriers
Perfluorocarbon-based Products
Artificial Blood Market, by Region
North America
Europe
Emerging Markets
Chapter 8 Emerging Technologies and Developments
Overview
Emerging Technologies
Nanocapsule Technology
Stem Cells
Other Ongoing Research for Blood Substitutes
Chapter 9 Product Analysis
Introduction
Product Safety
Product Effectiveness
Product Cost
Legal Implications
Product Analysis of Some of the Products Under Development
Hemopure
HemO2life
HemoTech
NanO2 (DDFPe)
Sanguinate
Vidaphor
Clinical Trials
Product Description of Some of the Products in Preclinical and Early Phase I Stage
ErythroMer
Hemoglobin vesicles
OxyVita
OxyBridge
Chapter 10 Patent Analysis
Introduction
FDA Regulation
FDA Good Manufacturing Practices and Reporting
Patent Analysis
Chapter 11 Competitive Intelligence
Strategic Developments
Competitive Analysis
Chapter 12 Company Profiles
AURUM BIOSCIENCES
ERYPHARM
HEMOGLOBIN OXYGEN THERAPEUTICS LLC.
HEMARINA
KALOCYTE INC.
NANO SANGUIS S.A
NUVOX PHARMA LLC.
PROLONG PHARMACEUTICALS, LLC
RED C BIOTECH
VIRTECH BIO
List of Tables
Summary Table : Global Market for Artificial Blood, Through 2028
Table 1 : Historical Events Related to Blood Transfusion, 1628-2022
Table 2 : Potential Benefits and Application Areas of Artificial Blood
Table 3 : Average Number of Blood Units Required During Particular Medical Conditions
Table 4 : The Challenges Associated with the Development of Artificial Blood
Table 5 : Common Challenges to the Blood Transfusion Continuum in LMICs.
Table 6 : Sources of Hemoglobin Molecules Used to Prepare Free Hemoglobin Solutions
Table 7 : Pros and Cons of Artificial Blood Developed from Human Blood
Table 8 : Pros and Cons of Artificial Blood Developed from Animal Blood
Table 9 : Pros and Cons of Artificial Blood Developed from Recombinant Blood
Table 10 : Summary of Acellular Hb-Based Oxygen Carriers
Table 11 : Examples of Hemoglobin-based Oxygen Carrier Products and Approval Status
Table 12 : Potential Clinical Applications of Oxygen Carriers
Table 13 : Composition of PFC Emulsion-Based Artificial Blood Products
Table 14 : First Generation Perfluorocarbon Emulsions Used in Medicine and Biology
Table 15 : Comparative Study of Second-Generation PFCs
Table 16 : PFC Emulsion Products and Current Status
Table 17 : Comparative Study Between RBCs and HBOCs
Table 18 : HBOC Solutions Transfusion: Side Effects and Possible Causes
Table 19 : Examples of HBOC Products Developed, by Various Companies
Table 20 : Global Market for Artificial Blood, Through 2028
Table 21 : Current Cell Sources and Strategies for Ex-vivo RBC Generation
Table 22 : List of Discontinued Blood Substitutes
Table 23 : Hemopure: Raw Material and Method Overview
Table 24 : Hemopure: Product Characteristics
Table 25 : Hemopure: Advantages and Disadvantages
Table 26 : Summary of Clinical Trials of Hemopure (HBOC-201), 2023
Table 27 : HemO2life: Raw Material and Method
Table 28 : HemO2life: Advantages and Disadvantages
Table 29 : HemO2life: Product
Table 30 : Ex vivo, In vivo and Clinical Studies involving HemO2life (M101) Use
Table 31 : Hemotech: Raw Material and Method Overview
Table 32 : HemoTech: Advantages and Disadvantages
Table 33 : NanO2 (DDFPe): Raw Material and Method Overview
Table 34 : NanO2 (DDFPe): Advantages and Disadvantages
Table 35 : NanO2 (DDFPe): Clinical Trials, 2023
Table 36 : Sanguinate: Raw Material and Method Overview
Table 37 : Sanguinate: Advantages and Disadvantages
Table 38 : Sanguinate: Clinical Trials, 2023
Table 39 : Vidaphor: Raw Material and Method Overview
Table 40 : Vidaphor: Advantages and Disadvantages
Table 41 : Vidaphor: Clinical Trials, 2023
List of Figures
Summary Figure : Global Market for Artificial Blood, 2020-2028
Figure 1 : The Blood Continuum
Figure 2 : Medical Use of Human Red Blood Cells in the U.S., 2019
Figure 3 : Estimated Number of New Cancer Cases from 2020 to 2040
Figure 4 : Discards of Blood Donations, by Reason, 2018
Figure 5 : Artificial Blood Manufactured from Different Sources
Figure 6 : History of HBOCs Developed Using Recombinant Technology
Figure 7 : Classification of Modified Hemoglobin Solution Based on Methods
Figure 8 : Classification of Different Types of Oxygen Carriers
Figure 9 : Generations of Perfluorocarbon Emulsions
Figure 10 : Advantages and Disadvantages of PFC Emulsions
Figure 11 : Evolution of HBOCs
Figure 12 : Advantages and Disadvantages of HBOCs
Figure 13 : Global Potential Market for Artificial Blood, by Application, 2028
Figure 14 : Biosynthetic RBC vs Artificial Blood Substitutes
Figure 15 : Artificial Blood: Parameters for Product Analysis
Figure 16 : Hemopure: Product Analysis
Figure 17 : HemO2life: Product Analysis
Figure 18 : NanO2 (DDFPe): Product Analysis
Figure 19 : Sanguinate: Product Analysis
Figure 20 : Current Competition in the Global Artificial Blood Market
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security